Andrew Huhn

Associate Professor

Johns Hopkins University School of Medicine

United States

Research Interests

Explore related searches

Professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Andrew Huhn is an Associate Professor at Johns Hopkins University School of Medicine, USA. His research focuses on substance use disorders, particularly the effects of various medications on opioid withdrawal, the role of stigma in treatment adherence, and the impact of insomnia on relapse and overdose risk. Recent publications include studies on the efficacy of suvorexant during opioid withdrawal, predictors of treatment attrition, and the physiological responses to opioid sensitivity.

Articles (17)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Collaborators (5)

Jennifer Ellis

Assistant Professor

Johns Hopkins University School of Medicine

UNITED STATES

View details

Justin C. Strickland

UNITED STATES

View details

Fangyu Liu

Johns Hopkins University

UNITED STATES

View details

Elise Weerts

Professor

Johns Hopkins University School of Medicine

UNITED STATES

View details

Denis Antoine

Johns Hopkins University

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Andrew Huhn

Research Interests

Explore related searches

Contact this professor

About

Articles (17)

Effects of suvorexant on diurnal cortisol and patient-reported stress during opioid withdrawal in a randomized trial

Perceived stigma and its role in substance use disorder treatment completion

Case Series: Magnitude and duration of fentanyl and xylazine detection in the urine of persons with opioid use disorder

Inter-individual divergence in thresholds for detecting opioid effects: Within-subject human laboratory evidence of a testable behavioral phenotype

Insomnia symptoms are associated with return to use and non-fatal overdose following opioid use disorder treatment

Predictors of treatment attrition among individuals in substance use disorder treatment: A machine learning approach

The association of pain impact and sleep disruption with opioid withdrawal during opioid‐use disorder treatment

Promoting sleep health to mitigate the risk of nonmedical opioid use and opioid-related adverse events

Within subject, double blind, examination of opioid sensitivity in participant-reported, observed, physiologic, and analgesic outcomes

A double-blind, randomized, placebo-controlled, pilot clinical trial examining buspirone as an adjunctive medication during buprenorphine-assisted supervised opioid withdrawal.

Can initial experiences with drugs predict future drug abuse risks?

Sleep disturbance as a therapeutic target to improve opioid use disorder treatment.

Commentary on Zolopa et al.: Trauma as an impediment to successful aging and a precipitant of opioid and stimulant use among older adults

Suvorexant ameliorated sleep disturbance, opioid withdrawal, and craving during a buprenorphine taper

Clinical correlates of drug‐related dreams in opioid use disorder

Adults With Opioid and Methamphetamine Co-use Have Lower Odds of Completing Short-Term Residential Treatment Than Other Opioid Co-use Groups: A Retrospective Health Services Study.

Latent trajectories of anxiety and depressive symptoms among adults in early treatment for nonmedical opioid use.

Collaborators (5)

Jennifer Ellis

Justin C. Strickland

Fangyu Liu

Elise Weerts

Denis Antoine

Make your next move.